Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus transarterial chemotherapy in pancreatic cancer with liver metastases
ChiCTR2600125023Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in pancreatic cancer (PC) and pancreatic cancer with hepatic metastases, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
pancreatic cancer (PC)pancreatic cancer with hepatic metastases
Beyond the preview
Go deeper on ChiCTR2600125023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125023.